Auswahl der wissenschaftlichen Literatur zum Thema „Minimal pharmacophores“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Minimal pharmacophores" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Minimal pharmacophores"
Mortier, Jérémie, Pratik Dhakal und Andrea Volkamer. „Truly Target-Focused Pharmacophore Modeling: A Novel Tool for Mapping Intermolecular Surfaces“. Molecules 23, Nr. 8 (06.08.2018): 1959. http://dx.doi.org/10.3390/molecules23081959.
Der volle Inhalt der QuellePetrikaite, Vilma, Eduardas Tarasevišius und Alvydas Pavilonis. „New ethacridine derivatives as the potential antifungal and antibacterial preparations“. Medicina 43, Nr. 8 (11.08.2007): 657. http://dx.doi.org/10.3390/medicina43080084.
Der volle Inhalt der QuelleSpasov, Alexander, Irina Ovchinnikova, Olga Fedorova, Yulia Titova, Denis Babkov, Vadim Kosolapov, Alexander Borisov et al. „Amino Derivatives of Diaryl Pyrimidines and Azolopyrimidines as Protective Agents against LPS-Induced Acute Lung Injury“. Molecules 28, Nr. 2 (11.01.2023): 741. http://dx.doi.org/10.3390/molecules28020741.
Der volle Inhalt der QuelleMishra, Pranjali, Muskan Srivastav, Yashveer Gautam, Monal Singh, Neeraj Verma, Deepak S. Kapkoti, Shailendra P. Singh, Anil K. Singh und Devendra P. Rao. „A REVIEW IN CURCUMINOIDS: CHEMISTRY, ANTICANCER ACTIVITY AND FUTURE PROSPECTS“. INDIAN DRUGS 61, Nr. 05 (28.05.2024): 7–23. http://dx.doi.org/10.53879/id.61.05.14041.
Der volle Inhalt der QuelleMaatuf, Yossi, Matan Geron und Avi Priel. „The Role of Toxins in the Pursuit for Novel Analgesics“. Toxins 11, Nr. 2 (23.02.2019): 131. http://dx.doi.org/10.3390/toxins11020131.
Der volle Inhalt der QuelleWermelinger, Guilherme Freimann, Lucas Rubini, Anna Carolina Carvalho da Fonseca, Gabriel Ouverney, Rafael P. R. F. de Oliveira, Acácio S. de Souza, Luana S. M. Forezi, Gabriel Limaverde-Sousa, Sergio Pinheiro und Bruno Kaufmann Robbs. „A Novel MDM2-Binding Chalcone Induces Apoptosis of Oral Squamous Cell Carcinoma“. Biomedicines 11, Nr. 6 (14.06.2023): 1711. http://dx.doi.org/10.3390/biomedicines11061711.
Der volle Inhalt der QuelleBourne, Yves, Gerlind Sulzenbacher, Laurent Chabaud, Rómulo Aráoz, Zoran Radić, Sandrine Conrod, Palmer Taylor, Catherine Guillou, Jordi Molgó und Pascale Marchot. „The Cyclic Imine Core Common to the Marine Macrocyclic Toxins Is Sufficient to Dictate Nicotinic Acetylcholine Receptor Antagonism“. Marine Drugs 22, Nr. 4 (27.03.2024): 149. http://dx.doi.org/10.3390/md22040149.
Der volle Inhalt der QuelleCaldas Lopes, Eloisi, Shieh Jae-Hung, Srikanth Ambati, Su Tsann-Long, Fabian Correa, Elizabeth Peguero und Malcolm A. S. Moore. „Novel Alkylating Agent, Ureidomustine Exhibit Pre-Clinical Efficacy in B-Cell Lymphoma with Minimal Dose-Limiting Myelotoxicity“. Blood 126, Nr. 23 (03.12.2015): 1556. http://dx.doi.org/10.1182/blood.v126.23.1556.1556.
Der volle Inhalt der QuelleVawhal, Pallavi Kishor, Shailaja B. Jadhav, Sumit Kaushik, Kahnu Charan Panigrahi, Chandan Nayak, Humaira Urmee, Sharuk L. Khan et al. „Coumarin-Based Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Pre-ADME Analysis, Toxicity Profile, Computational Analysis, and In Vitro Enzyme Assay“. Molecules 28, Nr. 3 (19.01.2023): 1004. http://dx.doi.org/10.3390/molecules28031004.
Der volle Inhalt der QuelleRobertson, Gregory T., Eric J. Bonventre, Timothy B. Doyle, Qun Du, Leonard Duncan, Timothy W. Morris, Eric D. Roche, Dalai Yan und A. Simon Lynch. „In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and Streptococci“. Antimicrobial Agents and Chemotherapy 52, Nr. 7 (Juli 2008): 2324–34. http://dx.doi.org/10.1128/aac.01651-07.
Der volle Inhalt der QuelleDissertationen zum Thema "Minimal pharmacophores"
Su, Li. „Generation of analogues of the anti-tumor polyketide stambomycins by genetic engineering and allied approaches“. Electronic Thesis or Diss., Université de Lorraine, 2021. http://www.theses.fr/2021LORR0081.
Der volle Inhalt der QuelleThe polyketide secondary metabolites of bacteria are a rich source of bioactive agents, with notable applications in anti-infective and anti-cancer therapy. However, their structures often need to be optimized in order to tailor their therapeutic and biophysical properties. The 51-membered macrolide stambomycins, among the largest of known polyketides, were recently discovered by genome mining in Streptomyces ambofaciens ATCC23877, and notably exhibit promising anti-cancer activity. The family encompasses six members which differ from each other in the alkyl functionality at C-26, due to the alternative choice of extender units by an exceptional acyl transferase domain (AT12) of the modular polyketide synthase (PKS) responsible for synthesizing the stambomycin core. Given their enormous size of the stambomycins and the intrinsic promiscuity of AT12, there is substantial interest in accessing ring-contracted and C-26 substituted derivatives of this compounds which might retain the bioactivity of the parental structures, or exhibit improved or even new properties. In this work, we have leveraged our current understanding of modular PKS systems to internally contract the stambomycin assembly line, leading to the successful generation, albeit at low yield, of target smaller derivatives (37-membered ‘mini-stambomycins’). By careful analysis, we could identify multiple factors contributing to the low titers, information which should inform future engineering strategies. Furthermore, using a mutasynthesis strategy, we were able to exploit the broad specificity of the AT12 domain to create 6 novel C-26 substituted stambomycin analogues. Finally, we unexpectedly identified three series of novel desferrioxamine siderophores produced by S. ambofaciens. As a number of key metabolites generated in this work have potential interest for therapeutic applications, they will be targeted for purification, structural characterization and biological evaluation
Buchteile zum Thema "Minimal pharmacophores"
Rijkers, Dirk T. S., Jack A. J. den Hartog und Rob M. J. Liskamp. „Structure-Activity Studies on the Corticotropin Releasing Factor Antagonist Astressin, Minimal Sequence Necessary for Antagonistic Activity: Implications for a New Pharmacophoric Model“. In Peptides: The Wave of the Future, 727–28. Dordrecht: Springer Netherlands, 2001. http://dx.doi.org/10.1007/978-94-010-0464-0_339.
Der volle Inhalt der Quelle